Vertex Pharmaceuticals Incorporated which can be found using ticker (VRTX) have now 25 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $577.00 and $325.00 suggesting an average analyst share price target price of $468.39. (at the time of writing). Given that the stocks previous close was at $467.28 and the analysts are correct then we can expect a percentage increase in value of .2%. The day 50 moving average is $433.08 and the 200 day moving average is $401.05. The company has a market capitalization of 121.64B. The stock price for the company is currently $471.38 USD
The potential market cap would be $121,929,969,427 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 30.59, revenue per share of $39.49 and a 12.82% return on assets.
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company has a pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.
